- Company
- Novartis, PNH drug 'Fabhalta' enters drug pricing nego.
- by Eo, Yun-Ho Apr 10, 2025 05:56am
- The new oral drug 'Fabhalta' has entered the last phase of receiving approval for insurance reimbursement. According to industry sources, Novartis Korea’s ’Fabhalta (iptacopan),’ a treatment for paroxysmal nocturnal hemoglobinuria (PNH), is under negotiations for drug pricing. Consequently, attention is gaining to whether another tr
- Company
- Will Leqvio not be reimbursed for ASCVD in Korea?
- by Eo, Yun-Ho Apr 9, 2025 05:56am
- The reimbursement of the twice-yearly dyslipidemia drug ‘Leqvio’ for ASCVD became unclear in Korea. According to Dailpharm coverage, the siRNA drug, Leqvio (inclisiran), from Novartis Korea failed to set reimbursement standards at the Drug Reimbursement Evaluation Subcommittee meeting of the Health Insurance Review and Assessment Servic
- Company
- Doctors long for a new treatment option for liver cancer
- by Moon, sung-ho Apr 9, 2025 05:56am
- Progressive hepatocellular carcinoma, or liver cancer, is a disease with only a few effective treatment options in the clinical setting. Recently, the emergence of various first-line treatment options such as targeted anticancer drugs and immuno-oncology drugs, has raised expectations for improved treatment outcomes. However, treatment option
- Company
- Trials for bispecific antibodies in cancer immunotherapy
- by Son, Hyung Min Apr 9, 2025 05:56am
- Yuhan, Hanmi Pharmaceuticals, and other domestic pharmaceutical and biotech companies have entered Phase 1 clinical trials of bispecific immuno-oncology drugs, delving into new drug development. Bispecific antibodies are drugs that can simultaneously bind to two different antigens or two distinct antigen-binding sites on the same antigen. Mul
- Company
- Samsung Bioepis launches Epysqli in the US
- by Whang, byung-woo Apr 9, 2025 05:56am
- Samsung Bioepis (CEO Kyung-ah Kim) announced on the 8th that it has launched Epysqli (project name SB12, ingredient name eculizumab), a treatment for rare diseases, in the US through its marketing partner, Teva. Epysqli is a biosimilar version of Soliris. Soliris is a treatment for rare diseases such as paroxysmal nocturnal hemoglobinuria
- Company
- ABL licenses out its tech to big pharmas worth ₩350B
- by Cha, Jihyun Apr 8, 2025 05:57am
- ABL Bio has signed a licensing-out agreement worth KRW 70 billion in advance payments (upfront). This is the company's 7th licensing-out agreement and its first platform deal. Including this contract, the cumulative technology fee ABL Bio earned through technology exports is close to KRW 350 billion. According to the Financial Supervisory
- Company
- ZP Therapeutics appoints Junghun Kim as new head
- by Eo, Yun-Ho Apr 8, 2025 05:57am
- The head of ZP&160;Therapeutics has been replaced after about 3 months. According to industry sources, Zuellig Pharma Korea recently appointed Junghun Kim (50), former Country Manager of Takeda Pharmaceutical Malaysia and Singapore, as the new General Manager of its commercial division, ZP Therapeutics. Hyunjoo Lee (48), the former CE
- Company
- China's mAb 'Hetronifly' secures orphan drug designation
- by Eo, Yun-Ho Apr 7, 2025 05:51am
- China-made immune checkpoint inhibitor has been designated as an orphan drug in South Korea. The Ministry of Food and Drug Safety (MFDS) recently announced on a notification board that it has granted Shanghai Henlius Biotech's 'Hetronifly (serplulima)' an orphan drug designation (ODD). The drug is indicated for 'use in combination with
- Company
- AbbVie Korea sales up twofold in two years
- by Son, Hyung Min Apr 7, 2025 05:51am
- With its new drugs for immune diseases, AbbVie Korea's sales have reportedly increased twofold in two years. AbbVie Korea is successfully transitioning generational changes for Humira follow-up of new drugs, including Skyrizi and Rinvoq. According to the Financial Supervisory Service on April 4, AbbVie recorded KRW 308.9 billion last year, up
- Company
- GPP drug Spevigo can be prescribed in general hospitals
- by Eo, Yun-Ho Apr 7, 2025 05:51am
- 'Spevigo', a treatment for Generalized Pustular Psoriasis (GPP), may now be prescribed in general hospitals in Korea. According to industry sources, the new drug for generalized pustular psoriasis (GPP) from Boehringer Ingelheim Korea, Spevigo (spesolimab), has recently passed the Drug Committee (DC) of the Seoul National University Hospi
